All anti-CD20 monoclonal antibodies have similar efficacy and risks: No
Research output: Contribution to journal › Comment/debate › Research › peer-review
Original language | English |
---|---|
Journal | Multiple Sclerosis Journal |
Volume | 28 |
Issue number | 12 |
Pages (from-to) | 1845-1846 |
Number of pages | 2 |
ISSN | 1352-4585 |
DOIs |
|
Publication status | Published - 2022 |
ID: 321283638